A Meta-analysis of the Association Between Adherence to Drug Therapy and Mortality

Overview

Journal BMJ

Specialty General Medicine

Date 2006 Jun 23

PMID 16790458

Citations 465

Authors

Scot H Simpson

Dean T Eurich

Sumit R Majumdar

Rajdeep S Padwal

Ross T Tsuyuki

Janice Varney

Jeffrey A Johnson

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the relation between adherence to drug therapy, including placebo, and mortality.

Design: Meta-analysis of observational studies.

Data Sources: Electronic databases, contact with investigators, and textbooks and reviews on adherence. Review methods Predefined criteria were used to select studies reporting mortality among participants with good and poor adherence to drug therapy. Data were extracted for disease, drug therapy groups, methods for measurement of adherence rate, definition for good adherence, and mortality.

Results: Data were available from 21 studies (46,847 participants), including eight studies with placebo arms (19,633 participants). Compared with poor adherence, good adherence was associated with lower mortality (odds ratio 0.56, 95% confidence interval 0.50 to 0.63). Good adherence to placebo was associated with lower mortality (0.56, 0.43 to 0.74), as was good adherence to beneficial drug therapy (0.55, 0.49 to 0.62). Good adherence to harmful drug therapy was associated with increased mortality (2.90, 1.04 to 8.11).

Conclusion: Good adherence to drug therapy is associated with positive health outcomes. Moreover, the observed association between good adherence to placebo and mortality supports the existence of the "healthy adherer" effect, whereby adherence to drug therapy may be a surrogate marker for overall healthy behaviour.

Citing Articles

The COVID-19 Pandemic Did Not Negatively Impact Adherence to Cardiovascular Medications Among 548,601 Chronically Treated Patients in Alberta.

McAlister F, Savu A, Chu L, Dover D, Kaul P CJC Open. 2025; 7(2):203-210.

PMID: 40060203 PMC: 11886360. DOI: 10.1016/j.cjco.2024.10.014.

The link between adherence to antihypertensive medications and mortality rates in patients with hypertension: a systematic review and meta-analysis of cohort studies.

Peng X, Wan L, Yu B, Zhang J BMC Cardiovasc Disord. 2025; 25(1):145.

PMID: 40033219 PMC: 11874117. DOI: 10.1186/s12872-025-04538-6.

All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data.

Alessandria M, Malatesta G, Di Palmo G, Cosentino M, Donzelli A F1000Res. 2025; 13:886.

PMID: 40028449 PMC: 11868741. DOI: 10.12688/f1000research.154058.2.

Medication adherence of patients with peripheral arterial disease to antithrombotic therapy: a systematic review.

Wegerif E, Mol B, Unlu C, de Borst G BMJ Open. 2025; 15(2):e085056.

PMID: 39987003 PMC: 11877208. DOI: 10.1136/bmjopen-2024-085056.

Relationship between social capital and medication adherence among frail and pre-frail older people: a cross-sectional study from China.

Hong Z, Guo Y, Cao W, Cao C, Hu Z, Yan J BMC Public Health. 2025; 25(1):477.

PMID: 39910502 PMC: 11800488. DOI: 10.1186/s12889-024-21253-7.

References

Ellis S, Shumaker S, Sieber W, Rand C . Adherence to pharmacological interventions. Current trends and future directions. The Pharmacological Intervention Working Group. Control Clin Trials. 2000; 21(5 Suppl):218S-25S. DOI: 10.1016/s0197-2456(00)00082-9. View

Ciechanowski P, Katon W, Russo J . Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000; 160(21):3278-85. DOI: 10.1001/archinte.160.21.3278. View

Moher D, Schulz K, Altman D . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001; 285(15):1987-91. DOI: 10.1001/jama.285.15.1987. View

Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R . Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002; 46(2):93-108. DOI: 10.1016/s0738-3991(01)00219-1. View

DiMatteo M, Giordani P, Lepper H, Croghan T . Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002; 40(9):794-811. DOI: 10.1097/00005650-200209000-00009. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

Simoni J, Frick P, Pantalone D, Turner B . Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2004; 11(6):185-98. View

DiMatteo M . Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004; 42(3):200-9. DOI: 10.1097/01.mlr.0000114908.90348.f9. View

Cramer J . A systematic review of adherence with medications for diabetes. Diabetes Care. 2004; 27(5):1218-24. DOI: 10.2337/diacare.27.5.1218. View

10.

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

11.

Rudd P . In search of the gold standard for compliance measurement. Arch Intern Med. 1979; 139(6):627-8. View

12.

Weintraub M . Intelligent noncompliance with special emphasis on the elderly. Contemp Pharm Pract. 1981; 4(1):8-11. View

13.

Conrad P . The meaning of medications: another look at compliance. Soc Sci Med. 1985; 20(1):29-37. DOI: 10.1016/0277-9536(85)90308-9. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Haynes R, Dantes R . Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials. 1987; 8(1):12-9. DOI: 10.1016/0197-2456(87)90021-3. View

16.

Echt D, Liebson P, Mitchell L, Peters R, BARKER A, Arensberg D . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781-8. DOI: 10.1056/NEJM199103213241201. View

17.

Donovan J . Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care. 1995; 11(3):443-55. DOI: 10.1017/s0266462300008667. View

18.

Miller N, Hill M, Kottke T, Ockene I . The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation. 1997; 95(4):1085-90. DOI: 10.1161/01.cir.95.4.1085. View

19.

McDermott M, Schmitt B, Wallner E . Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med. 1997; 157(17):1921-9. View

20.

Boudes P . Drug compliance in therapeutic trials: a review. Control Clin Trials. 1998; 19(3):257-68. DOI: 10.1016/s0197-2456(98)00005-1. View